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Immune diseasesISG15, the product of interferon (IFN)-stimulated gene 15, is the ﬁrst identiﬁed ubiquitin-like protein,
consisting of two ubiquitin-like domains. ISG15 is synthesized as a precursor in certain mammals and,
therefore, needs to be processed to expose the C-terminal glycine residue before conjugation to target proteins.
A set of three-step cascade enzymes, an E1 enzyme (UBE1L), an E2 enzyme (UbcH8), and one of several E3
ligases (e.g., EFP andHERC5), catalyzes ISG15 conjugation (ISGylation) of a speciﬁc protein. These enzymes are
unique among the cascade enzymes for ubiquitin and other ubiquitin-like proteins in that all of them are
induced by type I IFNs or other stimuli, such as exposure to viruses and lipopolysaccharide. Mass spectrometric
analysis has led to the identiﬁcation of several hundreds of candidate proteins that can be conjugated by ISG15.
Some of them are type I IFN-induced proteins, such as PKR and RIG-I, and some are the key regulators that are
involved in IFN signaling, such as JAK1 and STAT1, implicating the role of ISG15 and its conjugates in type I IFN-
mediated innate immune responses. However, relatively little is known about the functional signiﬁcance of
ISG15 induction due to the lack of information on the consequences of its conjugation to target proteins. Here,
we describe the recent progress made in exploring the biological function of ISG15 and its reversible modi-
ﬁcation of target proteins and thus in their implication in immune diseases.82 2 871 9193.
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Since the discovery of type I interferons (IFNα and IFNβ) in 1957,
they have widely been used as clinical drugs [1,2]. For example, IFNα
has been used for the treatment of chronic hepatitis B and hepatitis C
viruses and of several cancers, such as leukemia, and IFNβ is effective
for treating multiple sclerosis. Type I IFNs exert their effects through
the activation of Janus tyrosine kinase (JAK)/signal transducer and
activator of transcription (STAT) signaling pathway [3]. Upon bind-
ing of the IFNs to their cell surface receptors (IFNAR), the receptor-
associated kinases JAK1 and tyrosine kinase 2 (TYK2) become acti-
vated and phosphorylate tyrosine residues in the cytoplasmic tails of
the receptor subunit, IFNAR1. The phosphorylated subunit provides
speciﬁc docking sites for the activation of STATs by JAK1/TYK2-
mediated phosphorylation [4,5]. Activated STATs dissociate from the
receptor and translocate into the nucleus, where they act as transcrip-
tion factors that bind to the promoter regions of IFN-stimulated genes
(ISGs) [6]. STAT1/STAT2 heterodimers associate with IFN regula-
tory factor 9 (IRF-9) to form the transcription complex IFN-stimulated
gene factor 3 (ISGF3), which binds to IFN stimulatory response ele-
ments (ISREs) within the promoters of ISGs [7]. On the other hand,
homodimers and heterodimers of STAT1 and STAT3 bind to gamma-
activated sequence (GAS) response elements [8]. The ISG proteinsgenerated by these pathways play key roles in the induction of innate
and adaptive immune responses [9,10].
Proteinmodiﬁcationsbyubiquitin andubiquitin-likeproteins (Ubls),
including SUMO and Nedd8, have emerged as critical regulatory
processes, such as in the control of cell cycle, stress response, signaling
transduction, and immune response [11–15]. Moreover, deregulation
of the modiﬁcation systems gives rise to numerous human diseases,
such as cancers, neurodegenerative diseases, and immune diseases.
Conjugation of ubiquitin and Ubls to target proteins involves three-
step cascade enzymes: ubiquitin- and Ubl-activating E1 enzymes,
ubiquitin- and Ubl-conjugating E2 enzymes, and ubiquitin- and Ubl E3
ligases. Protein modiﬁcations by ubiquitin and Ubls are reversible
processes that are catalyzed by isopeptidases, called deubiquitinating
enzymes (DUBs) and Ubl-speciﬁc proteases (ULPs), respectively.
ISG15, a member of the Ubl family, shows a signiﬁcant sequence
homology to ubiquitin. Like ubiquitin, ISG15 is conjugated to numer-
ous cellular proteins via isopeptide bonds. This ISG15 conjugation
(ISGylation) utilizes UBE1L as E1 enzyme, UbcH8 as E2 enzyme, and
some ubiquitin E3 ligases, such as EFP and HERC5, as E3 enzymes
(Fig. 1). On the other hand, UBP43 (also called USP18) acts as a major
ISG15-speciﬁc deconjugating enzyme. ISG15 is not present in yeast,
nematode (Caenorhabditis), or insect (Drosophila), indicating that the
functions of ISG15 and itsmodiﬁcation are restricted to higher animals
with evolved IFN signaling.
ISG15 is strongly induced by type I IFNs [16,17]. Viral infection
also strongly induces ISG15 [18,19] because one of its major host
responses is the production of type I IFNs. A number of proteins
Fig. 1. Protein modiﬁcation by ISG15. ISG15-speciﬁc proteases cleave off the C-terminal
extensions from ISG15 precursors to generate matured ISG15 molecules. ISG15 is acti-
vated by UBE1L (E1) at the expense of ATP and is subsequently linked to the activating
enzyme via thiosester bond. ISG15 linked to UBE1L is transferred to UbcH8 (E2) and
then to a target proteinwith the aid of an ISG15 E3 ligase, such as EFP andHERC5. UBP43
functions in the reversal of the ISGylation process by cleaving off ISG15 molecules that
are conjugated to the substrate proteins via isopeptide bonds.
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MDA-5, Mx1, PKR, STAT1, and JAK1, have been identiﬁed as target
proteins for ISGylation. Moreover, recent studies have explored the
biological functions of ISG15 and its conjugation to target proteins.
ISG15 and its conjugation impair viral replication in vivo [20–26].
Conversely, certain viruses induce viral speciﬁc proteins that can
deconjugate ISG15 from its target proteins or prevent the genera-Fig. 2. Comparison of the amino acid sequence of ISG15 with that of ubiquitin and FAT10. (
acids are indicated by dark blue and the identical amino acids are by light blue. (B) Schema
ﬂexible linker region containing a Pro residue. (C) The amino acid sequences of ISG15 from v
the C-terminal extensions of 5–8 amino acids, whereas ISG15 molecules from bovine and ﬁtion of ISGylated proteins, thus abrogating the antiviral response
[18,27,28]. However, functional consequences of reversible ISG15
modiﬁcation of most target proteins, which are induced by viral in-
fection, are still largely unknown.
One of the key components of the innate immune response in
regulating cancer development is the activation of type I IFN
signaling pathways [29,30]. Type I IFNs suppress cell proliferation
and promote apoptosis and, therefore, have been used in the
treatment of several cancers, such as leukemia [31]. Notably, ISG15
appears to function as an oncogenic protein as well as a tumor
suppressor protein [32]. The ﬁndings that cancer chemotherapeu-
tics cause an increase in the level of ISG15 conjugates suggest the
role of ISG15 as a tumor suppressor [33–37]. Conversely, the
observations that deregulated overexpression of ISG15 and en-
hanced ISGylation are positively correlated with carcinogenesis
implicate the oncogenic potential of ISG15 protein [38–40].
However, since IFNs are induced on the development of many
cancers and ISG15 is an interferon-inducible protein, the enhanced
expression of ISG15 and its conjugation could be a side product of IFN
response to cancer andmay not play a general role in carcinogenesis.
Thus, further studies are required for clariﬁcation of the functional
relationship between ISG15 and carcinogenesis.
2. ISG15, the product of interferon-stimulated gene 15
2.1. Properties of ISG15
ISG15 was originally identiﬁed by Farrell et al. [16]. Because some
antibodies directed against ubiquitin also react with ISG15, it was
initially named as an ubiquitin cross-reactive protein (UCRP) [17].
This cross-reactivity is explained by the fact that the 15-kDa ISG15
protein consists of two domains, each of which bears high sequence
homology to ubiquitin. The primary sequences of the two ubiquitin-
like domains that correspond to theN- andC-terminal regions of ISG15
share 29% and 31% identities with ubiquitin, respectively (Fig. 2).
Furthermore, both the N- and C-terminal domains of ISG15 show a
striking similarity in their tertiary structures to ubiquitin (Fig. 3) [41].
Like ISG15, FAT10, which is also a member of the Ubl family,A) The amino acid sequences of ubiquitin, ISG15, and FAT10 are aligned. Similar amino
tic diagram shows the N- and C-terminal ubiquitin-like domains that are ﬂanked by a
arious species are aligned. Note that ISG15 molecules from human, mouse, and rat have
sh do not.
Fig. 3. Comparison of the tertiary structure of ISG15 with that of ubiquitin. (A) ISG15 alone. (B) Ubiquitin alone. (C) Ubiquitin is overlapped to the N- and C-terminal domains of
ISG15. (D) All of ubiquitin and the N- and C-terminal domains of ISG15 are overlapped. Information for structures was from the protein data bank (PDB): ubiquitin from UCH-L3-Ub
complex (PDB code: 1XD3) and ISG15 (PDB code: 1Z2M). The photographic images were made by using the PyMol program.
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limited number of cellular proteins [43,44].
Like ubiquitin, ISG15 proteins in some species are synthesized
as precursors that need to be processed before conjugation to
target proteins (Fig. 2) [45]. While ISG15 molecules in human,
mouse, and rat are translated as precursors containing the ex-
tensions of5–8 amino acids in their C-termini, ISG15 proteins in
most other species, including ﬁsh and bovine, are synthesized as
matured forms [46]. The C-terminal LRLRGG sequence of ISG15,
as that of ubiquitin, is essential not only for its conjugation to
substrates but also for its recognition by the relevant processing
proteases. However, this hexapeptide sequence is absent in the
analogous position of the N-terminal domain. Instead, a Pro re-
sidue is present at the position 81 of ISG15, thus preventing the
incorrect processing that might generate the two cleaved ubiquitin-
like domains of the 15-kDa polypeptide [47].
The C-terminal ubiquitin-like domain is sufﬁcient for its activation
by UBE1L and subsequent thioesteriﬁcation of UBE1L and UbcH8 [48].
When overexpressed, the C-terminal domain of ISG15 can be con-
jugated to cellular proteins. However, the level of cellular proteins
conjugated by the C-terminal domain alone is much lower than
that by full-length ISG15, suggesting that both domains of ISG15 are
required for efﬁcient conjugation to cellular proteins.
Interestingly, the replacement of Arg153 in human ISG15 (Arg151
in mouse) by Ala ablates the binding of ISG15 to UBE1L and sub-
sequent transesteriﬁcation of UbcH8 [49]. Accordingly, the ability
of the mutant ISG15 to form protein conjugates in 293T cells is
markedly diminished. Furthermore, while expression of wild-type
ISG15 protects IFNAR−/−mice from lethality after Sindbis virus (SNV)
infection, expression of the Arg-to-Ala mutant form of ISG15 confers
no survival beneﬁt. This mutation also attenuates the ability of ISG15
to decrease SNV replication in IFNAR−/−mice or prolong the survival
of ISG15−/− mice. Thus, Arg153 appears to serve as a binding site for
UBE1L.2.2. Control of ISG15 induction
Type I IFNs are capable of inducing ISG15 [47]. Notably, the induc-
tion of ISG15 shows biphasic kinetics. After IFNβ treatment, the in-
crease in the level of free ISG15 molecules is ﬁrst observable within
2 h, continues for the next 10 h, and becomes maximal by about 18 h.
On the other hand, ISG15 conjugates are observable at least 12 h after
the exposure to IFNβ, and their level dramatically increases between
12 and 18 h and continuously increases thereafter although at a slower
rate. This delayed induction of ISG15 conjugates indicates the require-
ment of ISG15-conjugating machinery that is expressed in the later
periods after the treatment with type I IFNs.
ISG15 is strongly induced by viral infection [18,19]. Like other
IFN-stimulated genes, the ISG15 gene has a 5′-cis-regulatory sequence
called ISRE (interferon-stimulated response element) [50]. A number
of IRFs, including IRF-3 and IRF-9, bind to the ISRE for ISG15 induction
(Fig. 4) [50–52]. IRF-3 forms a complex with CBP/p300 coactivators
for ISG15 induction [53,54]. On the other hand, IRF-9 interacts with
STAT1 and STAT2, leading to the formation of ISGF3 complex that also
induces ISG15. Upon dsRNA treatment, however, IRF-3 induces ISG15
independently of IFNs [55].
ISG15 is also strongly induced by lipopolysaccharide (LPS) [56–
58]. When macrophages are stimulated by LPS, ISG15 can be detec-
ted as early as 1 h and its level becomes maximal at about 4 h
[59]. Infection of mice with bacille Calmette–Guérin (BCG) markedly
induces ISG15 in macrophages. Moreover, this bacterial infection
leads to ISGylation of serpin2a (serine protease inhibitor 2a), which
was the ﬁrst identiﬁed target protein, although its biological
signiﬁcance remains unknown. ISGylation of serpin2a may protect
macrophages from lysosomal enzymes because a variety of lysosomal
proteases are upregulated by IFNγ for the destruction of ingested
bacteria and other pathogens. In addition, it has been shown that Trif/
IRF-3 signaling pathway is responsible for LPS-mediated induction of
ISG15 and its conjugation to target proteins [60].
Fig. 4. Viral immune-evading proteins. NS3/4A is involved in the cleavage of IPS-1, thus blocking the RIG-I signaling for IRF-3-mediated induction of type I IFN as well as of ISG15.
NS1B inhibits the thioesteriﬁcation of UBE1L and thereby the generation of ISG15 conjugates that are required for antiviral response. PLpro, OTU protease, and viral E3 protein
mediate the removal of ISG15 from its conjugates.
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that recapitulate aspects of the pre-B to immature B-cell transition in
response to NF-κB activation, but not in 1.3E, which is a NF-κB sig-
naling defective mutant cell line, indicating that NF-κB activation is
required for ISG15 induction [56]. Ataxia telangiectasia (AT) is a mul-
tifaceted autosomal recessive genetic disorder, characterized by the
loss of coordination, progressive neuronal degeneration, immunode-
ﬁciency, and cancer proneness [61]. NF-κB is constitutively activated
in human ﬁbroblasts derived from AT patients [62]. Moreover, the
level of ISG15 is constitutively elevated in the AT cells [63]. Because
activated NF-κB is capable of inducing the expression of type I IFNs,
it appears that the elevation of ISG15 level in the AT cells is due to
abnormal production of type I IFNs.
ISG15 also is a target geneof p53 [64–66]. Activation of temperature-
sensitive p53 leads to ISG15 induction in the absence of exogenous
stimuli. Since cycloheximide treatment does not inﬂuence the increase
in the level of ISG15 mRNA, ISG15 induction appears to be a primary
response to p53. While type I IFNs induce the accumulation of ISG15
mRNA in both wild-type or p53-deﬁcient cells, dsRNA induces it only
in wild-type cells, indicating that p53 is required for ISG15 induction
by dsRNA but not for that by type I IFNs. In addition, sequence analy-
sis of the human ISG15 gene has led to the identiﬁcation of a putative
p53-responsive element that is located adjacent to the ISG15-speciﬁc
ISRE [50]. Thus, in virus-infected cells, p53 seems to exert its antiviral
function by the induction of ISG15 in addition to the induction of
apoptotic signaling [67].
JNK induces the expression of ISGs, such as ISG15, ISG12, and IGTP
[68]. Swiss 3T3 cells expressing constitutively active MKK7–JNK1β
fusion protein show increased resistance to apoptosis induced by
vesicular stomatitis virus (VSV) infection, suggesting the involvementof JNK signaling pathway in antiviral response. Recently, PI3K has
been shown to control both IFNα- and IFNγ-induced expression of
ISGs, including ISG15, at both transcriptional and translational levels
[69]. IFN-mediated antiviral response is defective in cells lacking
p85α/p85β, the regulatory subunits of PI3K, suggesting the involve-
ment of PI3K signaling pathway in innate immune response.
ISG15 is induced by certain genotoxic stresses. For example, treat-
ment with camptothecin, an inhibitor of topoisomerase I, leads to an
increase in the level of ISG15mRNA, and this increase requires protein
synthesis and a functional p53 protein [35]. Interestingly, IFNs and
JAK/STAT are dispensable for camptothecin-mediated induction of
ISG15. ISG15 conjugates generated by camptothecin are distinct
from those produced by type I IFNs, suggesting that different protein
substrates are targeted for ISGylation. However, camptothecin
markedly increases IFN-induced ISGylation of cellular proteins.
Furthermore, treatment with both IFNs and camptothecin causes
synergistic killing of colorectal cancer xenografts in nude mice,
suggesting that the combination of the drugs can be an effective
therapeutic strategy [36].
Retinoic acid upregulates the levels of ISG15, its conjugates, and
UBE1L in acute promyelocytic cells [33,34]. The retinoic acid-mediated
accumulation of ISG15 and its conjugates occurs in retinoic acid-sen-
sitive leukemic cells but not in retinoic acid-resistant cells and the
pattern of accumulated ISG15 conjugates is similar to that observed
by the exposure to type I IFNs. In addition, several of the type I IFN-
induced proteins, such as IRF-1 and (2′-5′) oligoadenylate synthetase,
are induced by retinoic acid [70–72]. Treatment with retinoic acid
also leads to an increased secretion of type I IFNs into culture media.
Blockade of IFNARwith a neutralizing antibody prevents retinoic acid-
mediated accumulation of ISG15 and its conjugates. Thus, retinoic
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ulating cells to secrete IFNs.
3. Enzymes for ISG15 modiﬁcation
3.1. ISG15-activating E1 enzyme
UBE1L is a 112-kDa protein that shows a 45% identity in amino
acid sequence to the human ubiquitin-activating E1 enzyme (UBE1)
[73]. UBE1L expressed in baculovirus forms a thioester bond with
ISG15 but not with ubiquitin [18], indicating that it is a speciﬁc ISG15-
activating E1 enzyme. In addition, UBE1L has a C-terminal ubiquitin-
fold domain that is required for the transfer of ISG15 from UBE1L to
UbcH8 as well as for the binding of UBE1L to UbcH8 [74]. As expected,
UBE1L-deﬁcient mice are not capable of producing ISG15 conjugates
upon stimuli [75]. In UBE1L−/− macrophages treated with LPS and
in UBE1L−/− mouse embryonic ﬁbroblasts (MEFs) treated with IFNs,
ubiquitination of cellular proteins occurs normally, but ISGylation
of proteins is completely abolished, conﬁrming the strict requirement
of UBE1L for ISGylation.
The UBE1L gene is located in the D3F15S2 locus of chromosome
3q21 [76]. UBE1L can be detected in the jejunum, colon, lung, liver,
tonsils, testis, and skin but not in the spleen and pancreas. Signiﬁ-
cantly, UBE1L is not detectable in all tested human lung cancer cell
lines [73,77], implicating a tumor-suppressive role of UBE1L. This
repressed expression in lung cancer cell lines is intriguing because a
region of chromosome 3q, in which the UBE1L gene resides, is often
deregulated in preneoplastic or neoplastic epithelial tissues [78]. How-
ever, upon generation of UBE1L−/−/K-rasLA2mice, it has recently been
shown that the loss of ISGylation does not affect tumor spectrum,
tumor pathology, or survival of K-rasLA2 mice [79]. Nonetheless, it is
possible that UBE1L deﬁciency and K-ras mutation are two separate
pathways in lung cancer development. Additional works with other
lung cancermousemodels are necessary to clarify the potential tumor
suppressor function of UBE1L in K-ras mutation-independent human
lung cancers.
3.2. ISG15-conjugating E2 enzymes
UbcH8, an ISG15-conjugating E2 enzyme, is induced by type I IFNs
and viral infection [80–82]. UbcH6 is also induced by type I IFNs and
forms a thioester intermediate with ISG15, suggesting that UbcH6 has
the potential to function as an ISG15-conjugating E2 enzyme [83].
However, the amount of the thioester intermediate formed by UbcH6
is much lower than that by UbcH8, indicating that UbcH8 is amajor E2
enzyme for ISG15.
UbcH8 was originally identiﬁed as an ubiquitin-conjugating E2
enzyme by a yeast two-hybrid screening for its interaction with E6AP
[84]. UbcH8 was later shown to also interact with other ubiquitin E3
ligases, such as Parkin, Dorﬁn, Staring, EFP, and RLIM and function as
an ubiquitin-conjugating E2 enzyme [85–90]. Thus, UbcH8 serves as
an E2 enzyme for both ubiquitin and ISG15. However, although UbcH7
is the most closely related E2 to UbcH8, it does not function in ISG15
conjugation [74]. Moreover, UbcH8 shows a higher afﬁnity to UBE1L
than UbcH7, while UbcH7 bindsmore strongly to UBE1 than UbcH8. In
addition, it has been shown that two structural elements within the
E2 N-terminal region are responsible for the differential interaction of
UbcH8 and UbcH7 with UBE1L. Thus, UbcH8 may preferentially, but
not exclusively, function as an E2 enzyme for ISG15.
Interestingly, UbcH8 and ISG15 can act as functional regulators
of RNF125, an ubiquitin E3 ligase of RIG-I [91]. In the absence of ISG15,
UbcH8 interacts with RNF125 and interferes with RIG-I ubiquitina-
tion. Upon overexpression of ISG15, however, the interaction of
UbcH8 with ISG15 leads to the dissociation of UbcH8 from RNF125,
thus allowing the association of RNF125 with UbcH5 for RIG-I
ubiquitination.3.3. ISG15 E3 ligases
The overlapping function of UbcH8 as an E2 enzyme for both
ubiquitin and ISG15 raises a possibility that some UbcH8-interacting
ubiquitin E3 ligases can also function as ISG15 E3 ligases. Indeed, the
UbcH8-interacting protein EFP (estrogen-responsive ﬁnger protein)
that has a RING ﬁnger domain serves as an ISG15 E3 ligase [92]. In the
absence of ISG15, UbcH8 and EFP may function as E2 and E3 enzymes
for ubiquitination, respectively. Upon ISG15 induction, however,
ISG15 may compete with ubiquitin for binding to UbcH8, allowing
UbcH8 and EFP to serve as the enzymes for ISGylation of 14-3-3σ.
Replacement of the active site Cys residue in the RINGdomain disrupts
EFP-mediated ISGylation of 14-3-3σ. Like UbcH8, EFP is a type I IFN-
inducible protein [93]. Interestingly, EFP can ISGylate itself on the
Lys117 residue and this auto-ISGylation negatively regulates the ISG15
E3 ligase activity of EFP toward 14-3-3σ, suggesting that a feedback
loop is operating for the control of the protein ISGylation [94,95].
An additional RING-containing ubiquitin E3 ligase, called HHARI
(human homolog of Drosophila ariadne), also serves as an ISG15 E3
ligase for 4EHP [96].
HERC5 (HECT domain and RCC1-like domain containing protein 5)
is an ISG15 E3 ligase that contains the HECT domain [97–99]. Like EFP,
HERC5 is a type I IFN-inducible protein. Knockdown of HERC5 by using
siRNA prevents IFN-mediated increase in the total level of ISGylated
cellular proteins, unlike that of EFP, which blocks the ISGylation of
14-3-3σ with little or no effect on the total level of ISGylated pro-
teins. Thus, it appears that HERC5 serves as a general IFN-induced
ISG15 E3 ligase. Like EFP, HERC5 itself is a target for ISGylation, but
its functional signiﬁcance is unknown.
3.4. ISG15-speciﬁc proteases
3.4.1. UBP43 and other ISG15-speciﬁc proteases
UBP43 cleaves off ISG15 from its protein conjugates that are linked
via isopeptide bonds [100]. UBP43 can also cleave the peptide bonds
immediately after the LRLRGG sequence in ISG15 fusions [100]. Thus,
UBP43 appears to also function in the processing of ISG15 precursors
to generate matured ISG15 molecules. However, apart from UBP43,
additional ISG15-speciﬁc proteases must exist because ISG15 precur-
sor is processed to its matured form in UBP43-deﬁcient mice [101].
The overlapping function of some E2 and E3 enzymes in the con-
jugation of both ISG15 and ubiquitin also implies the existence of
promiscuous DUBs that can serve as ISG15-speciﬁc proteases. Indeed,
several DUBs, including USP2, USP5, USP13, and USP14, have been
identiﬁed as the candidates that can function as ISG15-processing
and/or deconjugating enzymes [102]. In addition, it has been reported
that recombinant ISG15 precursors can be properly processed by a
100-kDa enzyme in the extracts of human lung ﬁbroblasts cell line
A549, whose activity is unaffected by type I IFN stimulation [103]. This
100-kDa enzyme is a cysteine protease and shows a partial similarity
in its amino acid sequence with that of the human ortholog of yeast
Ubp1 or Ubp1-related protein. However, deletion of the UBP43 gene
in mouse leads to a massive increase of ISG15 conjugates in tissues
without affecting the level of ubiquitin conjugates, indicating that
UBP43 is the major ISG15-speciﬁc protease that deconjugates ISG15
from its target proteins. Thus, it appears likely that the above-men-
tioned DUBs as well as the 100-kDa cysteine protease function pri-
marily in the processing of ISG15 precursors to generate matured
ISG15 molecules.
UBP43 is induced by type I IFNs, and this induction requires a func-
tional JAK/STAT signaling pathway [104]. IFNβ induces UBP43 more
strongly than IFNα and dsRNA, but IFNγ barely induces it [105]. UBP43
is also induced by LPS [58]. IRF-3 is responsible for LPS-mediated
induction of UBP43, while IRF-2 is involved in its induction to a basal
level. However, both IRF-2 and IRF-3 are required for optimal respon-
siveness to LPS. Interestingly, UBP43 induction is upregulated by
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created by t(8;21), suggesting a possible involvement of UBP43 in
hematopoiesis [106]. However, it is unknown how AML1-ETO affects
the up-regulation of UBP43 induction. In addition, UBP43 has been
identiﬁed as a substrate for Skp2 [107]. Skp2 promotes the ubiquitina-
tion of UBP43 and subsequent degradation by the proteasomes, sug-
gesting that the SCFSkp2 may be involved in the regulation of type I IFN
signaling by controlling the stability of UBP43.
The human UBP43 gene maps to the chromosome 22q11.2 [108].
This region, known as DiGeorge syndrome critical region, is consis-
tently deleted in DiGeorge syndrome and related disorders, sug-
gesting that UBP43 may be involved in the development of thymus or
differentiation of T cells.
3.4.2. UBP43 as a negative regulator of innate immune responses
UBP43-deﬁcient mice are viable and resistant to the fatal lympho-
cytic choriomeningitis and myeloencephalitis that develop in wild-
type mice upon intracerebral inoculation of lymphocytic choriome-
ningitis virus (LCMV) and VSV, respectively [101,109]. Furthermore,
survival of UBP43−/− mice after LCMV infection correlates with
severe inhibition of LCMV replication as well as with an increase in the
level of ISG15 conjugates in the brain. None of the UBP43−/− mice
infected with LCMV died or developed clinical symptoms by day 11
after infection, whereas all LCMV-infected wild-type mice died by day
7 infection. These ﬁndings strongly suggest that UBP43 deﬁciency
causes an unfavorable environment for LCMV replication. In addition,
UBP43−/−MEF cells exhibit enhanced type I IFN-mediated resistance
to cytopathic effect caused by VSV and SNV. These ﬁndings strongly
suggest that UBP43 serves as a negative regulator of innate immune
response against viral infection. However, the enhanced resistance
to viral infection in UBP43−/− mice cannot be rescued in UBP43−/−/
ISG15−/− or UBP43−/−/UBE1L−/− double knockouts, indicating that
the phenotypic alterations are not associated with the protein modi-
ﬁcation by ISG15 [75,110]. Thus, UBP43, independently of its isopep-
tidase activity, may have another biological function.
UBP43−/− cells are hypersensitive to type I IFNs, resulting in a
dramatic increase in the level of ISGylatedproteins,which is associated
with the enhanced and prolonged JAK/STAT signaling [111]. How-
ever, UBP43, independently of its catalytic activity, also functions as a
negative regulator of type I IFN signaling [112]. This UBP43 action is
achieved through a direct interaction between UBP43 and IFNAR2, a
subunit of type I IFN receptor. Binding of IFNAR2 to UBP43 interferes
with the interaction between JAK and the receptor, leading to the
inhibition of downstream phosphorylation cascade and other sig-
naling events. In addition, complementation of UBP43−/− cells with a
catalytically inactive mutant of UBP43 leads to the inhibition of STAT1
phosphorylation to a level seen by that with wild-type UBP43. More-
over, down-regulation of the total level of ISG15 conjugates by siRNA-
mediated knockdown of UBE1L in UBP43−/− cells shows little or no
effect on STAT1 phosphorylation in comparison with that seen in
UBP43+/+ cells, indicating that the deISGylating activity of UBP43
is not required for its inhibitory effect on type I IFN signaling. This
conclusion is further corroborated with the ﬁndings that phenotypic
alterations inUBP43−/−mice are not inﬂuenced by the lack of ISG15 in
UBP43−/−/ISG15−/− double knockout mice [75,110].
The isopeptidase-independent action of UBP43 is also involved in
the replication of HBV (hepatitis B virus) [113]. UBP43−/− cells show
an increased induction of ISGs in response to type I IFNs, indicating
that the lack of UBP43 results in a strengthened immune response.
Consistently, the steady-state level of HBV DNA is substantially re-
duced in UBP43−/−mice in comparison with that in UBP43+/+ mice.
Thus, approaches that modulate UBP43 level could be used as thera-
peutic potentials in treating viral infection, especially for viruses
sensitive to type I IFN signaling. In addition to the protection against
HBV, UBP43 deﬁciency increases the resistance to oncogenic trans-
formation by BCR–ABL (breakpoint cluster region Abelson leukemiaprotein), a fusion protein consisting of the N-terminal portion of BCR
joined to most of the ABL tyrosine kinase [114]. This resistance to
leukemia development is heavily dependent on the activation of type I
IFN signaling pathway. Loss of type I IFN signaling through the loss of
IFNAR results in a reversal of the original resistance to the leukemia
development observed in mice that received a transplant of BCR–ABL-
expressing UBP43-deﬁcient donor cells. Thus, it appears that inhi-
bition of the negative effect of UBP43 on type I IFN signaling could
enhance innate immune response against cancer development.4. Biological functions of ISG15 and its conjugation
By using a combination of afﬁnity puriﬁcation and mass spectro-
metry, hundreds of target proteins for ISGylation have been identiﬁed.
Some of them are type I IFN-induced proteins, including PKR, MxA,
Hup56, and RIG-I [115]. Some are key regulators that are involved in
type I IFN signaling, such as PLCγ1, JAK1, ERK1, and STAT1 [116]. Most
other targets are constitutively expressed and function in diverse
cellular pathways, including translation, glycolysis, cell motility, pro-
tein modiﬁcation, intracellular protein trafﬁcking, RNA splicing, chro-
matin remodeling, cytoskeletal organization, and stress responses
[97,115,117]. These ﬁndings implicate the role of protein ISGylation
in type I IFN-induced immune responses as well as in the control of
numerous fundamental cellular pathways.
4.1. ISG15 as a cytokine modulating immune responses
ISG15 is synthesized in many cell types and secreted from human
monocytes and lymphocytes [118]. Both native and recombinant
ISG15 induce the synthesis and secretion of IFNγ from B-cell-depleted
lymphocytes, implicating the role of ISG15 as a cytokine that modu-
lates immune response [119]. Treatment with human ISG15, but not
its precursor form, leads to an increase in DNA synthesis in cultured
primary blood lymphocytes in a dose-dependent fashion, suggesting
that ISG15 can act as a mitogen and that the processing of ISG15
precursor is required for the generation of biologically active ISG15
[120]. Furthermore, ISG15 has been identiﬁed as a member of the
cytokine cascades. Upon viral infection, type I IFNs produced in in-
fected cells induce the synthesis of ISG15. These ISG15 molecules can
be secreted or released by lysis of the infected cells. They may then
induce the production of IFNγ from T cells, augment NK cell pro-
liferation, activate non-major histocompatibility complex-restricted
cytolytic lymphocytes, and activate monocytes and macrophages via
the induced IFNγ.
4.2. Regulation of signal transduction pathways
Filamins are nonmuscle actin-binding proteins that comprise a
family of three members: ﬁlamin A, B, and C [121,122]. These ﬁlamin
isoforms are large cytoplasmic proteins that play important parts in
cross-linking cortical actin ﬁlaments into a dynamic three-dimen-
sional structure. Recently, it has been shown that ﬁlamin B func-
tions as a scaffold that links between activated Rac1 and a JNK cascade
module for mediating type I IFN signaling [123,124]. Filamin B inter-
acts with Rac1, MEKK1, MKK4, and JNK and enhances their sequential
activation in response to type I IFNs, thereby promoting JNK activation
and apoptosis. This acceleration of JNK-mediated apoptosis provides a
biological basis for antitumor and antiviral functions of type I IFNs.
Furthermore, it has been revealed that type I IFNs induce ISGylation
of ﬁlamin B, which leads to dissociation of Rac1, MEKK1, and MKK4
from the scaffold protein and thus to the prevention of prolonged
activation of type I-induced JNK signaling pathway [124,125]. In con-
trast, blockade of ﬁlamin B ISGylation by substitution of the ISG15
acceptor site Lys2467 with Arg or by siRNA-mediated knockdown of
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resulting in persistent promotion of JNK activation and JNK-mediated
apoptosis. These ﬁndings indicate that ISGylation of ﬁlamin B serves
as a negative feedback regulatory gate for desensitization of type I
IFN-induced JNK signaling, thus providing an important mechanism
for the survival of uninfected bystander cells.
PP2Cβ dephosphorylates TAK1 and suppresses TAK1/TAB1-
mediated IκBαdegradation, thus controllingNF-κB signaling pathway,
which plays a critical role in innate and adaptive immunity and cancer
[126–129]. PP2Cβ is a target for ISGylation, and thismodiﬁcation blocks
the suppressive function of the protein phosphatase against TAK1/
TAB1-mediated NF-κB activation [130]. This conclusion is based on
the observation that overexpression of UBE1L, UbcH8, and ISG15
blocks the suppressive effect of PP2Cβ on NF-κB activation, but
not that of its mutant, in which the ISG15 acceptor sites Lys12 and
Lys142 are replaced by arginine. Thus, ISGylation of PP2Cβ seems to
play a role in the control of NF-κB pathway.
4.3. Regulation of ubiquitination
Ubc13, an ubiquitin-conjugating E2 enzyme, is a target for
ISGylation [131,132]. ISG15 is conjugated to Lys92 of Ubc13, which
is very closely located to its active site, thus preventing the forma-
tion of a thioester bond with ubiquitin. Since Mms2, which forms a
heteromeric complexwith Ubc13, interacts with both unmodiﬁed and
ISGylated Ubc13, the inhibitory effect of Ubc13 ISGylation on the
thioesteriﬁcation of ubiquitin seems to be achieved by the inability
of ISGylated Ubc13 to accept ubiquitin to its active site or by blocking
the recognition of ubiquitin E1 enzyme and subsequent transfer of
ubiquitin from the E1 enzyme to Ubc13. Ubc13 is known to mediate
the generation of Lys63-linked poly-ubiquitin chains that are con-
jugated to a variety of signaling molecules [133,134]. Thus, it is pos-
sible that ISGylation of Ubc13 may play an important role in the
control of signal transduction pathways, such as NF-κB pathway,
which are associated with Lys63-linked poly-ubiquitination [132].
UbcH8 and UbcH6 also are targets for ISGylation [83]. ISGylation of
UbcH6 occurs in response to type I IFNs and blocks the thioesteriﬁ-
cation of ubiquitin, like that of Ubc13, suggesting that ISGylation of
UbcH6 may also lead to the suppression of its ubiquitin-conjugating
activity.
4.4. Regulation of antiviral responses
Initial efforts that intend to determine the role of ISG15 in antivi-
ral responses appeared unsuccessful. UBE1L−/− mice are fertile and
exhibit normal antiviral responses against VSV and LCMV infection,
indicating that UBE1L and protein ISGylation may not be essential
for IFN signaling [75]. Furthermore, ISG15−/−mice are also fertile and
display no obvious abnormalities [135]. Lack of ISG15 does not affect
the development and composition of the main cellular immune sys-
tem. The IFN-induced antiviral and immune responses directed against
VSV and LCMV are not signiﬁcantly altered in the absence of ISG15. In
addition, IFN- or endotoxin-induced STAT1 phosphorylation as well as
the expression of typical STAT1 target genes remain unaffected by the
lack of ISG15, indicating that ISG15 is dispensable for STAT1-mediated
IFN signaling. However, the function of ISG15 as an antiviral effector
has come to the front.
Unlike the infection by VSV and LCMV, UBE1L−/− mice display
markedly increased susceptibility to inﬂuenza B virus infection, with
only 25% survival of UBE1L−/− mice for 21 days, compared to 86%
survival of UBE1L+/+ mice [20]. Furthermore, both of the kinetics of
lethality and the overall survival of UBE1L−/− mice are identical to
those of ISG15−/− mice, indicating that the antiviral activity of ISG15
against inﬂuenza B virus is mediated by its conjugation to target pro-
teins. The predominant site of ISG15 action during inﬂuenza virus
infection resides within a stromal cell population. A likely candidateis the respiratory epithelium, since it is the site of inﬂuenza virus
replication. This is the ﬁrst phenotype described for UBE1L−/− mice,
which were previously found to have no defect in response to VSV
or LCMV infection [75]. In addition, it has recently been shown that
both the synthesis of inﬂuenza A virus protein and the early rate of
the virus replication are inhibited by ISG15 conjugation of cellular
proteins [21].
ISG15−/−mice also exhibit increased susceptibility to infection by
a number of other viruses, such as inﬂuenza A/WSN/33 and B/Lee/40
viruses, herpes simplex virus type 1 and murine gamma herpes virus
68, and SNV [22]. In addition, ISG15 is induced after SNV infection, and
this induction is markedly attenuated in IFNAR−/− mice, indicating
that induction of ISG15 by SNV infection is dependent on type I IFNs
[136]. ISG15 induction protects against SNV-induced lethality and
decreases the virus replication in multiple organs. The increased sus-
ceptibility of IFNAR−/− mice to SNV infection can be rescued by
the expression of wild-type ISG15 having the C-terminal diglycine
residues but not by that of an ISG15 mutant, of which the C-terminal
diglycine is replaced by dialanine, again indicating that the antiviral
action of ISG15 requires its conjugation to target proteins.
Type I IFN-mediated inhibition of human immunodeﬁciency
virus (HIV) assembly and release has been shown to correlate with
the induction of ISG15 [23]. Furthermore, overexpression of ISG15
mimics the IFN effect and inhibits the release of HIV-1 virions without
having any effect on the synthesis of the viral proteins in infected cells
[24]. In cells infected with HIV-1 provirus, overexpression of ISG15
and UBE1L causes a complete inhibition of HIV-1 replication. On the
other hand, coexpression of UBP43 can partially rescue the release
of HIV-1 in ISG15-expressing cells. Intriguingly, ISG15 expression
speciﬁcally inhibits the ubiquitination of Gag and Tsg101 and disrupts
their interaction, thereby preventing assembly and release of virions
from infected cells. Expression of ISG15 alone (i.e., without UBE1L)
does not block the viral release, indicating that ISGylation of target
proteins, but not ISG15 itself, is required for the inhibition of Gag
ubiquitination, although ISGylation of either Gag or Tsg101 could not
be detected. Thus, ISGylation of certain unknown viral and/or host
proteins appears to play a critical role in the IFN-mediated inhibition
of HIV-1 assembly and release.
Overexpression of ISG15 or UBE1L with UbcH8 has been shown to
inhibit budding of Ebola virus VP40 virus-like particles (VLPs) [25,26].
Ebola virus is a member of the Filoviral family of negative-sense RNA
viruses. The VP40 matrix protein is a key structural protein that is
critical for the virion release. The efﬁcient budding of VLPs requires
the interaction of overlapping L-domains (late-budding domains) in
the VP40 protein with Nedd4, an ubiquitin E3 ligase, as well as with
other members of the ESCRT pathway (e.g., Tsg101) [137–140]. ISG15
overexpression decreases not only the level of VP40 detected in VLPs
but also the levels of endogenous Nedd4 incorporated into budding
VP40 VLPs. Nedd4 interacts with and is conjugated by ISG15. More-
over, ISG15 overexpression blocks the ability of Nedd4 to ubiquiti-
nate VP40, leading to the prevention of L-domain-mediated budding
of VP40 VLPs. In addition, it has been shown that free ISG15 specif-
ically binds to Nedd4 and inhibits the interaction of the E3 ligase with
ubiquitin E2 enzymes (e.g., UbcH6), thus preventing the transfer of
ubiquitin from the E2 enzymes to Nedd4 [26]. These ﬁndings reveal
a mechanism for the antiviral function of ISG15 that involves the
ISGylation and inactivation of the host Nedd4 E3 ligase.
IRF-3 is a target for ISGylation, which can be induced by both
type I IFNs and viral infection [141]. This ISGylation prevents the
ubiquitination and degradation of IRF-3 in NDV (Newcastle disease
virus)-infected human ﬁbrosarcoma 2fTGH cells, and promotes the
translocation of IRF-3 to the nucleus, where it binds to the IFNβ
promoter. The relative level of IRF-3 is signiﬁcantly lower in NDV-
infected ISG15−/− cells than in ISG15+/+ cells, indicating that
the subversion of antiviral response is mediated by proteolysis of
IRF-3. Moreover, the degradation of IRF-3 can be counteracted by
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mechanism for the induction of host antiviral response by ISGyla-
tion-dependent stabilization of IRF-3.
However, ISG15 is typically conjugated to only a small fraction
of target proteins. Therefore, an important issue is how the small frac-
tions of ISGylated proteins, including IRF-3, can exert their biological
functions. It has been proposed that if the small fractions of proteins
that are modiﬁed by Ubls (e.g., SUMO and ISG15) are localized to
some functionally unique cellular site or the transient modiﬁcation
is sufﬁcient to switch the protein into new state, their functions
could efﬁciently operate [124,142,143]. Intriguingly, overexpression
of ISG15 leads to the appearance of IRF-3 as punctates in the nucleus
[141]. This nuclear retention could allow IRF-3 to exert its profound
antiviral function, although only a small portion of IRF-3 is ISGylated
upon the viral infection. An additional example is that upon over-
expression of ﬁlamin B, UbcH8 is recruited tomembrane rufﬂes where
ﬁlamin B is also concentrated with actin [123,125]. This recruitment
of UbcH8, which otherwise resides throughout the cytoplasm and
the nucleus, should allow the E2 enzyme to efﬁciently function in
ﬁlamin B ISGylation and thus in desensitization of type I IFN-induced
JNK signaling (see above).
The inducible nitric oxide synthase (iNOS) is not expressed under
normal conditions, but like ISG15, it is induced by various stimuli,
such as exposure to cytokines, microbes, or microbial products, result-
ing in the sustained production of NO [144]. Upon stimuli, NO as well
as the products generated by its interaction with ROS, such as pero-
xynitrite and peroxynitrous acid, are accumulated and utilized for
the antibacterial or antiviral effects [144–146]. NO is also covalently
attached to the thiol group of cysteine residues of proteins, causing
their S-nitrosylation. This posttranslational modiﬁcation serves as an
important mechanism that mediates antibacterial and antiviral effects
through the alteration in enzymatic activity, protein–protein interac-
tion, and signal transduction [147]. Interestingly, the cysteine residue
in ISG15 can also bemodiﬁed by NO and this S-nitrosylation decreases
the dimerization of ISG15, thereby increasing the availability as well
as the solubility of monomeric ISG15 for its conjugation to cellular
proteins [148]. Moreover, treatment with S-ethylisothiourea, an iNOS
inhibitor, reduces the level of ISG15 conjugates, whereas overexpres-
sion of iNOS increases it. Thus, iNOS may play a role in the enhance-
ment of innate immune responses bymediating ISG15 S-nitrosylation.
4EHP is an mRNA 5′cap structure-binding protein and acts as a
translation suppressor by competing with eIF4E for binding to the cap
structure [149]. 4EHP is a target protein for ISGylation and this modi-
ﬁcation substantially increases its cap structure–binding activity [96].
This is the ﬁrst report that shows “gain of function” by IFN-induced
ISGylation, thus providing a mechanism by which a small fraction of
any ISGylated protein can generate profound biological effects in
response to IFNs or pathogen infections. Interestingly, 4EHP fusedwith
ISG15 at either of its N- or C-terminus dramatically enhances the cap
structure–binding activity, indicating the ISG15 fusion protein can
mimic the ISGylated 4EHP. Since IFNs inhibit the translation of viral
mRNAs while allowing normal translation of the majority of cellular
mRNAs [150], it is possible that ISGylated 4EHP acts as a viral mRNA-
speciﬁc translation inhibitor in a cap binding-dependent manner.
RIG-I senses intracellular virus-speciﬁc nucleic acid structures and
as an early antiviral response induces the production of type I IFNs,
which in turn activates the expression of RIG-I, thus generating a
positive feedback loop for further accumulation of RIG-I [151–155].
Intracellular dsRNA activates NF-κB and IRF-3/IRF-7 through RIG-I
and the mitochondrial adaptor protein IFN promoter stimulator 1
(IPS-1) [156–159]. Furthermore, RIG-I is a target protein for ISGyla-
tion [115,160]. However, ISGylation of RIG-I leads to a reduction in the
levels of both basal and virus-induced IFN production. Consistently,
the basal mRNA and protein levels of RIG-I are signiﬁcantly higher in
UBE1L−/− cells than in UBE1L+/+ cells. Based on these observations, it
has been proposed that a negative feedback loop is operating for ﬁne-tuning the strength of RIG-I-mediated signaling to maintain a balance
between innate immune response and hypersensitivity during anti-
viral responses. In addition, ubiquitination of RIG-I by TRIM25 is re-
quired to mediate antiviral signaling responses, whereas that by
RNF125 results in the proteasomal degradation of RIG-I [161]. Thus,
multiple positive and negative mechanisms appear to contribute
to the maintenance of optimal RIG-I level and thus to the control of
RIG-I-mediated signaling.
4.5. Viral immune-evading mechanisms
Viruses escape from the antiviral activity of ISG15 by using dif-
ferent mechanisms. Inﬂuenza B virus strongly induces ISG15 during
infection but speciﬁcally blocks ISGylation of host proteins [18]. This
inhibition is mediated by the viral NS1B protein, which interacts with
ISG15 and prevents the generation of ISG15 conjugates under in vitro
conditions as well as in infected cells (Fig. 4). Puriﬁed NS1B inhibits
the formation of ISG15-UBE1L-like thioester intermediate. ISG15
conjugates accumulate in IFN-treated cells, but not in cells infected by
inﬂuenza B virus, although similar amounts of ISG15 are synthesized
in both cells. Moreover, ISG15 conjugates are not detectable in cells
infected with the virus expressing full-length NS1B but are markedly
accumulated in cells infected with the virus expressing truncated
NS1B, which cannot bind to ISG15, indicating that the interaction of
NS1B with ISG15 is responsible for the inhibition of ISG15 conjugation
and thus of the antiviral function of ISG15.
SARS-coronavirus (SARS-CoV) produces a papain-like protease,
called PLpro, which can generate an authentic ISG15 molecule by
cleaving off a protein that is fused to the C-terminus of ISG15 [162].
It is possible that the activity of PLpro may mimic the ISG15-deconju-
gating activity of UBP43, thus favoring viral replication by counter-
acting protein ISGylation.
Vaccinia virus (VACV) E3 protein is an early protein that inter-
acts with ISG15 through its C-terminal domain [28]. Whereas siRNA-
mediated knockdown of ISG15 enhances the viral replication, com-
plementation of ISG15 to ISG15−/− cells attenuates it. Notably, the
level of ISG15 conjugates is much higher in ISG15-complemented
ISG15−/− cells infected with the E3-deﬁcient virus than that with
the wild-type virus, suggesting that VACV E3 protein is directly or
indirectly involved in deconjugation of ISG15 from cellular pro-
teins. Moreover, the virus lacking E3 protein that is unable to grow in
ISG15+/+ cells can replicate in ISG15−/− cells. These ﬁndings suggest
a new strategy for poxviruses to evade the host antiviral response
through the viral E3 protein-mediated control of protein ISGylation.
The ovarian tumor domain (OTU)-containing proteases fromnairo-
viruses and arterviruses, two unrelated groups of RNA viruses, are
capable of deconjugating ubiquitin and ISG15, but not SUMO, from
cellular target proteins [27]. Puriﬁed OTU protease cleaves off ubi-
quitin from both Lys48- and Lys63-linked poly-ubiquitin chains in
vitro. Remarkably, the expression of OTU protease antagonizes the
antiviral effects of ISG15 and enhances the susceptibility to SNV
infection. It has been shown that approximately 70% of IFNAR−/−
mice survive after infection of the virus expressing both ISG15 and an
OTU variant, of which the catalytic Cys residue is replaced by Ala. In
contrast, only 20% of the mice survive when infected with the virus
expressing both ISG15 and wild-type OTU protease, indicating that
the antiviral response is mediated by ISG15, but not by other ISGs,
and that the immune-evading effect of OTU protease requires its
catalytic activity. These ﬁndings indicate that SNV uses OTU protease
as a unique strategy to evade the host antiviral response.
Hepatitis C virus (HCV) is an enveloped virus that causes liver
diseases, including cancer [163,164]. RIG-I signaling induces a host
response that controls HCV RNA replication [165]. However, HCV can
evade this response in part through its ability to antagonize the relay
of RIG-I signaling to IRF-3 [166]. NS3/4A, a major serine protease ex-
pressed by HCV [164], cleaves IPS-1, causing the release of cleaved
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results in the subcellular redistribution of IPS-1 and loss of its inter-
action with RIG-I, thereby preventing downstream activation of IRF-3
and IFNβ induction. Intriguingly, in liver tissues chronically infected
by HCV, the IPS-1 cleavage and its subcellular redistribution are asso-
ciated with the lack of ISG15 and its conjugates. Among the HCV-
infected tissues, ISG15 and its conjugates can be detected only in the
liver from patients, which has predominantly uncleaved, full-length
IPS-1 protein. These ﬁndings indicate that NS3/4A plays a critical role
in evading the host antiviral response by attenuating the IFN ampli-
ﬁcation loop of RIG-I and thus the expression of ISGs, including ISG15,
which are normally induced by RIG-I- and IRF-3-dependent pathways.
4.6. ISG15 in tumorigenesis
4.6.1. ISG15 as a tumor suppressor
UBE1L has been shown to play an important role in the sup-
pression of lung cancer growth. UBE1L overexpression inhibits the
growth of human bronchial epithelial cells and lung cancer cells.
Furthermore, UBE1L promotes cyclin D1 ISGylation and this modiﬁ-
cation leads to the destabilization of cyclin D1, indicating that UBE1L
confers growth suppression by targeting cyclin D1 [169]. These ﬁnd-
ings provide a mechanism for the tumor-suppressive role of UBE1L
[37,73,77,170], although it is unknown how the stability of cyclin D1 is
affected by its ISGylation.
Acute promyelocytic leukemia (APL) is characterized by the accu-
mulation of oncogenic PML/RARα fusion protein [171,172]. Retinoic
acid induces UBE1L and subsequent ISGylation of PML/RARα [33,34,
37]. Moreover, UBE1L-mediated ISGylation of PML/RARα leads to a
decrease in the level of PML/RARα, thus overcoming the oncoge-
nic effects of the fusion protein [173,174]. On the other hand, treat-
ment with N-acetyl-Leu-Leu-norleucinal, a proteasome inhibitor,
prevents the degradation of ISGylated PML/RARα, indicating that
the proteasomes are involved in the control of PML/RARα stability.
These ﬁndings implicate an important role of UBE1L in the suppres-
sion of leukemia.
4.6.2. ISG15 as an oncogenic factor
In many tumors and tumor cell lines, ISG15 is highly elevated and
extensively conjugated to cellular proteins [39]. The level of ISG15
mRNA is signiﬁcantly higher in cancerous mammary epithelial cells
lines, such as BT20, MDA-MB468, MDA-MB231, T47D, andMCF7, than
in nonmalignant mammary cell lines, including HMEC and MCF10A.
The level of ISG15 protein is also higher in breast tumors than in
normal tissues [175]. In addition, a correlation between increased
ISG15 level and unfavorable prognosis in the survival of patients has
been reported, suggesting a potential role of ISG15 in breast cancer
development, although the role of ISG15 in breast carcinogenesis is
unknown.
Signiﬁcantly, the increased level of ISG15 in tumor cells is asso-
ciated with the decreased levels of ubiquitinated proteins, suggesting
that ISG15 plays an antagonistic role against ubiquitin-mediated pro-
teolysis and that deregulation of ubiquitin–proteasome pathway is
related with tumorigenesis [39]. Since some of the E2 (e.g., UbcH8)
and E3 enzymes (e.g., EFP) can utilize both ubiquitin and ISG15 for
conjugation to target proteins, it seems possible that ISG15 may
potentially interfere with the ubiquitination pathway at the level of
E2 and E3 enzymes, thus decreasing the level of ubiquitinated pro-
teins in tumor cells.
However, it has been shown that the level of ubiquitin conjugates
in UBP43−/− cells is nearly the same as that in UBP43+/+ cells [116],
despite the fact that treatment with type I IFNs leads to a dramatic
accumulation in the level of ISG15 conjugates in UBP43−/− cells as
compared with that in UBP43+/+ cells. Furthermore, treatment with
lactacystin, an inhibitor of the proteasome, shows little or no effect on
the level of ISG15 conjugates in either of UBP43+/+ or UBP43−/− cellswhether or not exposed to IFNβ, while as expected the level of ubi-
quitinated proteins markedly increases in both cells. Thus, it appears
that ISG15 and its conjugates by themselves do not interfere with the
ubiquitination of cellular proteins and their subsequent degradation.
The reason for the tumor-speciﬁc overexpression of ISG15 in dif-
ferent tumors is unclear. One possibility is that the elevated express-
ion of ISG15 may be due to constitutively activated NF-κB in many
tumor cells. This possibility is supported by an observation that ISG15-
overexpressing ZR-75-1 cells show a greater NF-κB activity than
ISG15-underexpressing BT474 breast cancer cells [176]. Alternatively,
the deregulated expression of UBE1L and UBP43 in certain tumors
could contribute to the variation in the levels of ISG15 conjugates in
tumor biopsy samples.
Androgen receptor has been implicated in the initiation and pro-
gression of prostate cancer [177,178]. Signiﬁcantly, UBE1L and UbcH8
are upregulated in prostate cancer lesions as compared to those in
corresponding nonmalignant tissues [179]. Moreover, overexpression
of UBE1L in LNCaP cells leads to a marked increase in the mRNA and
protein levels of androgen receptor in addition to an increase in the
rate of cell proliferation. On the other hand, siRNA-mediated knock-
down of ISG15 and UBE1L in LNCaP cells results in a signiﬁcant de-
crease in the transcript and protein levels of androgen receptor. These
ﬁndings suggest that ISGylation machinery participates in a positive
control of androgen receptor expression during the onset of prostate
cancers, thereby promoting the tumor growth.
5. Concluding remarks
Since the discovery of IFNs, a vast knowledge on the role of the
cytokines in innate immune responses has been accumulated. ISG15 is
one of the most strongly induced ISGs upon exposure to type I IFNs,
virus, LPS, and other stresses, including certain genotoxic stresses
[16,17,35,56,64,180]. Considering that type I IFNs play critical roles
in innate immune responses regulating the antiviral responses as
well as the cancer development, there is no doubt that ISG15 and
its conjugation to target proteins play critical roles in the type I IFN-
induced immune responses. However, the biological signiﬁcance of
protein modiﬁcation by ISG15 has been established only in several
cases. Therefore, much studies are required for clariﬁcation of the
role of ISG15 in innate immune responses against viral infection and
cancer and thus for the control of immune diseases as well as for
resolving the contradictory ﬁndings, such as the role of ISG15 as a
tumor suppressor versus an oncogenic protein.
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